The earnings call reflects positive trends in financial performance, especially with record gross profit and strong international growth. However, it is overshadowed by challenges in the Canadian market and significant concerns over activist shareholder issues. This creates a mixed outlook, with strong operational performance but potential strategic risks.

Company Guidance

During the MediPharm Labs Conference Call discussing Q1 2025 results, CEO David Pidduck highlighted several key financial metrics that demonstrate the company's strategic progress. The gross profit in Q1 2025 was CAD 4.2 million, constituting a 38.7% gross margin, the highest achieved in many years. The company also reported a positive adjusted EBITDA of CAD 141,000, marking a significant improvement from a CAD 949,000 loss in the prior year. Revenue increased by 10.6% year-over-year to CAD 10.8 million, with international medical cannabis revenue surging by 87% to CAD 5.9 million, now representing 55% of total revenue. Moreover, general and administrative expenses were reduced by 29% compared to the previous year, and the company maintained a strong cash balance of CAD 8.4 million with virtually no debt, positioning MediPharm for further growth and M&A opportunities.

Record Gross Profit and Margin

Gross profit in Q1 2025 reached CAD4.2 million or 38.7% of sales, marking the highest gross margin achieved in many years, up from a negative margin when the CEO joined in 2022.

EBITDA Positive Milestone

Adjusted EBITDA for Q1 2025 was positive CAD141,000, improved by CAD1.1 million from the previous year's loss of CAD949,000.

Strong International Revenue Growth

International medical cannabis revenue increased by CAD2.8 million or 87% year-over-year to CAD5.9 million, representing 55% of total revenue.

VIVO Acquisition Success

The acquisition of VIVO in 2023 has been fully integrated and is cited as a transformational success, contributing significantly to international growth.

Strong Balance Sheet and Financial Health

MediPharm has a strong balance sheet with CAD8.4 million in cash, virtually no debt, and full ownership of three production facilities.

MediPharm Labs (MEDIF) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

MEDIF Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 17, 2025	2025 (Q3)	0.00 / -	-0.005	―	―	―
Aug 14, 2025	2025 (Q2)	>-0.01 / >-0.01	-0.007	0.00% (0.00)	―
May 14, 2025	2025 (Q1)	- / -	-0.007	―	―
Mar 31, 2025	2024 (Q4)	>-0.01 / 0.00	-0.007	―	―	―
Nov 14, 2024	2024 (Q3)	>-0.01 / >-0.01	-0.007	30.00% (<+0.01)	―	―
Aug 14, 2024	2024 (Q2)	>-0.01 / >-0.01	-0.007	0.00% (0.00)	―
May 15, 2024	2024 (Q1)	>-0.01 / >-0.01	-0.007	0.00% (0.00)	―
Mar 27, 2024	2023 (Q4)	>-0.01 / >-0.01	-0.015	55.00% (<+0.01)	―
Nov 14, 2023	2023 (Q3)	>-0.01 / >-0.01	-0.022	66.67% (+0.01)	―
Aug 14, 2023	2023 (Q2)	-0.01 / >-0.01	-0.022	66.67% (+0.01)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

MEDIF Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$0.06	$0.06	0.00%
May 14, 2025	$0.07	$0.08	+14.29%
Mar 31, 2025	$0.07	$0.07	0.00%
Nov 14, 2024	$0.05	$0.05	0.00%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does MediPharm Labs (MEDIF) report earnings?

MediPharm Labs (MEDIF) is schdueled to report earning on Nov 17, 2025, TBA (Confirmed).

What is MediPharm Labs (MEDIF) earnings time?

MediPharm Labs (MEDIF) earnings time is at Nov 17, 2025, TBA (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is MEDIF EPS forecast?

MEDIF EPS forecast for the fiscal quarter 2025 (Q3) is 0.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing